173 related articles for article (PubMed ID: 29298771)
21. Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.
Gockley A; Melamed A; Bregar AJ; Clemmer JT; Birrer M; Schorge JO; Del Carmen MG; Rauh-Hain JA
Obstet Gynecol; 2017 Mar; 129(3):439-447. PubMed ID: 28178043
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective.
Elstrand MB; Sandstad B; Oksefjell H; Davidson B; Tropé CG
Acta Obstet Gynecol Scand; 2012 Mar; 91(3):308-17. PubMed ID: 22050605
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
[TBL] [Abstract][Full Text] [Related]
26. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
Hynninen J; Lavonius M; Oksa S; Grénman S; Carpén O; Auranen A
Gynecol Oncol; 2013 Feb; 128(2):229-32. PubMed ID: 23142076
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
Rauh-Hain JA; Foley OW; Winograd D; Andrade C; Clark RM; Vargas RJ; Hinchcliff EM; Esselen KM; Horowitz NS; del Carmen MG
Am J Obstet Gynecol; 2015 May; 212(5):600.e1-8. PubMed ID: 25514761
[TBL] [Abstract][Full Text] [Related]
28. Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Gynecol Oncol; 2018 Jan; 148(1):62-67. PubMed ID: 29174056
[TBL] [Abstract][Full Text] [Related]
29. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
30. Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
Jamieson A; Sykes P; Eva L; Bergzoll C; Simcock B
Gynecol Oncol; 2017 Aug; 146(2):273-278. PubMed ID: 28549816
[TBL] [Abstract][Full Text] [Related]
31. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
32. Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian Cancer; potential impact of patient blood management on Cancer outcomes.
Connor JP; O'Shea A; McCool K; Sampene E; Barroilhet LM
Gynecol Oncol; 2018 Nov; 151(2):294-298. PubMed ID: 30201233
[TBL] [Abstract][Full Text] [Related]
33. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
[TBL] [Abstract][Full Text] [Related]
34. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
Seagle BL; Graves S; Strohl AE; Shahabi S
Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
[TBL] [Abstract][Full Text] [Related]
35. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
36. Neutrophil-to-lymphocyte ratio as a prognostic factor in advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy.
Salman L; Sabah G; Jakobson-Setton A; Raban O; Yeoshoua E; Eitan R
Int J Gynaecol Obstet; 2020 Jan; 148(1):102-106. PubMed ID: 31571212
[TBL] [Abstract][Full Text] [Related]
37. Racial disparities in the treatment of advanced epithelial ovarian cancer.
Howell EA; Egorova N; Hayes MP; Wisnivesky J; Franco R; Bickell N
Obstet Gynecol; 2013 Nov; 122(5):1025-1032. PubMed ID: 24104782
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
Milam MR; Tao X; Coleman RL; Harrell R; Bassett R; Dos Reis R; Ramirez PT
Int J Gynecol Cancer; 2011 Jan; 21(1):66-71. PubMed ID: 21178571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
